We also publish - a lot

[1]

Erber, J., Stecher, C., Plajer, V., Braun, N., Mallard, W., Goff, L.A., et al. 2025. Rroid2 regulates effector-to-memory CD8+ T cell differentiation during infection in vivo. Proceedings of the National Academy of Sciences of the United States of America. 122(48:e2503450122. https://doi.org/10.1073/pnas.2503450122.

[2]

Rosner, A., Skos, L., Mendrina, T., Baier, D., Hejl, M., Borutzki, Y., et al. 2025. Selectivity for TP53 signalling drives the mode of action of a highly potent N,O,O-tridentate naphthoquinone-based organo-ruthenium anticancer drug candidate. Chemical Science. https://doi.org/10.1039/d5sc00735f.

[3]

Gastaldi, T., Novoszel, P., Sanlorenzo, M., de Sá Fernandes, C., Mohr, T., Krauß, D., et al. 2025. Multi-omics and functional characterization of the tumor-killing capacity of Imiquimod-activated plasmacytoid dendritic cells. iScience. 28(6:112670. https://doi.org/10.1016/j.isci.2025.112670.

[4]

Krauß, D., Moreno-Viedma, V., Adachi-Fernandez, E., de Sá Fernandes, C., Genger, J.-W., Fari, O., et al. 2025. EGFR controls transcriptional and metabolic rewiring in KRASG12D colorectal cancer. EMBO molecular medicine. 17(6:1355–1392. https://doi.org/10.1038/s44321-025-00240-4.

[5]

Hagn, G., Bileck, A., Mohr, T., Schmidl, D., Baron, D.M., Jilma, B., et al. 2025. Time Course of Plasma Proteomic and Oxylipin Changes Induced by LPS Challenge and Modulated by Antioxidant Supplementation in a Randomized Controlled Trial. Antioxidants (Basel, Switzerland). 14(5:536. https://doi.org/10.3390/antiox14050536.

[6]

Hagn, G., Cho, A., Zila, N., Sterniczky, B., Jantschitsch, C., Dong, D., et al. 2025. Extracorporeal photopheresis induces the release of anti-inflammatory fatty acids and oxylipins and suppresses pro-inflammatory sphingosine-1-phosphate. Inflammation Research: Official Journal of the European Histamine Research Society ... [et Al.]. 74(1:40. https://doi.org/10.1007/s00011-025-02007-6.

[7]

Nasrollahi-Shirazi, S., Unterwurzacher, M., Berezhinskiy, H.O., Alemanno, S., Hoetzenecker, K., Aigner, C., et al. 2025. Serum proteomics analysis of lung transplant patients receiving different induction therapies. Frontiers in Immunology. 16:1616781. https://doi.org/10.3389/fimmu.2025.1616781.

[8]

Akman, M., Monteleone, C., Doronzo, G., Godel, M., Napoli, F., Merlini, A., et al. 2024. Correction: TFEB controls sensitivity to chemotherapy and immuno-killing in non-small cell lung cancer. Journal of experimental & clinical cancer research: CR. 43(1:244. https://doi.org/10.1186/s13046-024-03170-0.

[9]

Akman, M., Monteleone, C., Doronzo, G., Godel, M., Napoli, F., Merlini, A., et al. 2024. TFEB controls sensitivity to chemotherapy and immuno-killing in non-small cell lung cancer. Journal of experimental & clinical cancer research: CR. 43(1:219. https://doi.org/10.1186/s13046-024-03142-4.

[10]

Schaubmayr, W., Hackl, M., Pultar, M., Ghanim, B.D., Klein, K.U., Schmid, J.A., et al. 2024. Candidate Signature miRNAs from Secreted miRNAome of Human Lung Microvascular Endothelial Cells in Response to Different Oxygen Conditions: A Pilot Study. International Journal of Molecular Sciences. 25(16:8798. https://doi.org/10.3390/ijms25168798.

[11]

Wimmer, B., Schernthaner, J., Edobor, G., Friedrich, A., Poeltner, K., Temaj, G., et al. 2024. RiboScreenTM Technology Delivers a Ribosomal Target and a Small-Molecule Ligand for Ribosome Editing to Boost the Production Levels of Tropoelastin, the Monomeric Unit of Elastin. International Journal of Molecular Sciences. 25(15:8430. https://doi.org/10.3390/ijms25158430.

[12]

Bortel, P., Hagn, G., Skos, L., Bileck, A., Paulitschke, V., Paulitschke, P., et al. 2024. Memory effects of prior subculture may impact the quality of multiomic perturbation profiles. Proceedings of the National Academy of Sciences of the United States of America. 121(29:e2313851121. https://doi.org/10.1073/pnas.2313851121.

[13]

Dinić, J., Dragoj, M., Jovanović Stojanov, S., Stepanović, A., Lupšić, E., Pajović, M., et al. 2024. Multidrug-Resistant Profiles in Non-Small Cell Lung Carcinoma Patient-Derived Cells: Implications for Personalized Approaches with Tyrosine Kinase Inhibitors. Cancers. 16(11:1984. https://doi.org/10.3390/cancers16111984.

[14]

Obermayr, E., Mohr, T., Schuster, E., Braicu, E.I., Taube, E., Sehouli, J., et al. 2024. Gene expression markers in peripheral blood and outcome in patients with platinum-resistant ovarian cancer: A study of the European GANNET53 consortium. International Journal of Cancer. https://doi.org/10.1002/ijc.34978.

[15]

Hagn, G., Meier-Menches, S.M., Plessl-Walder, G., Mitra, G., Mohr, T., Preindl, K., et al. 2024. Plasma Instead of Serum Avoids Critical Confounding of Clinical Metabolomics Studies by Platelets. Journal of Proteome Research. https://doi.org/10.1021/acs.jproteome.3c00761.

[16]

Schaubmayr, W., Hochreiter, B., Hunyadi-Gulyas, E., Riegler, L., Schmidt, K., Tiboldi, A., et al. 2024. The Proteome of Extracellular Vesicles Released from Pulmonary Microvascular Endothelium Reveals Impact of Oxygen Conditions on Biotrauma. International Journal of Molecular Sciences. 25(4:2415. https://doi.org/10.3390/ijms25042415.

[17]

Zila, N., Eichhoff, O.M., Steiner, I., Mohr, T., Bileck, A., Cheng, P.F., et al. 2024. Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research. 30(1:159–175. https://doi.org/10.1158/1078-0432.CCR-23-0562.

[18]

Baier, D., Mendrina, T., Schoenhacker-Alte, B., Pirker, C., Mohr, T., Rusz, M., et al. 2023. The Lipid Metabolism as Target and Modulator of BOLD-100 Anticancer Activity: Crosstalk with Histone Acetylation. Advanced Science (Weinheim, Baden-Wurttemberg, Germany). 10(32:e2301939. https://doi.org/10.1002/advs.202301939.

[19]

Mödl, B., Awad, M., Zwolanek, D., Scharf, I., Schwertner, K., Milovanovic, D., et al. 2023. Defects in microvillus crosslinking sensitize to colitis and inflammatory bowel disease. EMBO reports. 24(10:e57084. https://doi.org/10.15252/embr.202357084.

[20]

Mosleh, B., Schelch, K., Mohr, T., Klikovits, T., Wagner, C., Ratzinger, L., et al. 2023. Circulating FGF18 is decreased in pleural mesothelioma but not correlated with disease prognosis. Thoracic Cancer. 14(22:2177–2186. https://doi.org/10.1111/1759-7714.15004.

[21]

Ries, A., Slany, A., Pirker, C., Mader, J.C., Mejri, D., Mohr, T., et al. 2023. Primary and hTERT-Transduced Mesothelioma-Associated Fibroblasts but Not Primary or hTERT-Transduced Mesothelial Cells Stimulate Growth of Human Mesothelioma Cells. Cells. 12(15:2006. https://doi.org/10.3390/cells12152006.

[22]

Caban, M., Koblmueller, B., Groza, D., Schueffl, H.H., Terenzi, A., Tolios, A., et al. 2023. A novel EGFR inhibitor acts as potent tool for hypoxia-activated prodrug systems and exerts strong synergistic activity with VEGFR inhibition in vitro and in vivo. Cancer Letters. 565:216237. https://doi.org/10.1016/j.canlet.2023.216237.

[23]

Soukup, R., Gerner, I., Mohr, T., Gueltekin, S., Grillari, J., Jenner, F. 2023. Mesenchymal Stem Cell Conditioned Medium Modulates Inflammation in Tenocytes: Complete Conditioned Medium Has Superior Therapeutic Efficacy than Its Extracellular Vesicle Fraction. International Journal of Molecular Sciences. 24(13:10857. https://doi.org/10.3390/ijms241310857.

[24]

Malik, B., Vokic, I., Mohr, T., Poppelaars, M., Holcmann, M., Novoszel, P., et al. 2023. FAM3C/ILEI protein is elevated in psoriatic lesions and triggers psoriasiform hyperproliferation in mice. EMBO Molecular Medicine. n/a(n/a:e16758. https://doi.org/10.15252/emmm.202216758.

[25]

Janker, L., Schuster, D., Bortel, P., Hagn, G., Meier-Menches, S.M., Mohr, T., et al. 2023. Multi-omics empowered deep phenotyping of ulcerative colitis identifies biomarker signatures reporting functional remission states. Journal of Crohn’s & Colitis. jjad052. https://doi.org/10.1093/ecco-jcc/jjad052.

[26]

Bortel, P., Hagn, G., Skos, L., Bileck, A., Paulitschke, V., Paulitschke, P., et al. 2023. Multi-Omics Data of Perturbation Studies are Determined by Memory Effects from Subculture. https://doi.org/10.1101/2023.02.13.528316.

[27]

Ries, A., Flehberger, D., Slany, A., Pirker, C., Mader, J.C., Mohr, T., et al. 2023. Mesothelioma-associated fibroblasts enhance proliferation and migration of pleural mesothelioma cells via c-Met/PI3K and WNT signaling but do not protect against cisplatin. Journal of experimental & clinical cancer research: CR. 42(1:27. https://doi.org/10.1186/s13046-022-02582-0.

[28]

Ertl, I.E., Brettner, R., Kronabitter, H., Mohr, T., Derdak, S., Jeitler, M., et al. 2022. The SMARCD Family of SWI/SNF Accessory Proteins Is Involved in the Transcriptional Regulation of Androgen Receptor-Driven Genes and Plays a Role in Various Essential Processes of Prostate Cancer. Cells. 12(1:124. https://doi.org/10.3390/cells12010124.

[29]

Moritsch, S., Mödl, B., Scharf, I., Janker, L., Zwolanek, D., Timelthaler, G., et al. 2022. Tyk2 is a tumor suppressor in colorectal cancer. OncoImmunology. 11(1:2127271. https://doi.org/10.1080/2162402X.2022.2127271.

[30]

Ertl, I.E., Lemberger, U., Ilijazi, D., Hassler, M.R., Bruchbacher, A., Brettner, R., et al. 2022. Molecular and Pharmacological Bladder Cancer Therapy Screening: Discovery of Clofarabine as a Highly Active Compound. European Urology. 82(3:261–270. https://doi.org/10.1016/j.eururo.2022.03.009.

[31]

Gabler, L., Jaunecker, C.N., Katz, S., van Schoonhoven, S., Englinger, B., Pirker, C., et al. 2022. Fibroblast growth factor receptor 4 promotes glioblastoma progression: A central role of integrin-mediated cell invasiveness. Acta Neuropathologica Communications. 10(1:65. https://doi.org/10.1186/s40478-022-01363-2.

[32]

Baier, D., Schoenhacker-Alte, B., Rusz, M., Pirker, C., Mohr, T., Mendrina, T., et al. 2022. The Anticancer Ruthenium Compound BOLD-100 Targets Glycolysis and Generates a Metabolic Vulnerability towards Glucose Deprivation. Pharmaceutics. 14(2:238. https://doi.org/10.3390/pharmaceutics14020238.

[33]

Galffy, M., Bichler, C., Mohr, T., Egeter, J., Neu, L., Oberhammer, M., et al. 2022. Ad hoc Setup of an Online Mental Health Self-Help Program During the COVID-19 Pandemic: Description of the Development and Implementation Processes and Analysis of Its Users’ and Usage Profiles. Frontiers in Psychology. 13:853371. https://doi.org/10.3389/fpsyg.2022.853371.

[34]

Uludağ, D., Bay, S., Sucu, B.O., İpek, Ö. Şavluğ, Mohr, T., Güzel, M., et al. 2022. Potential of Novel Methyl Jasmonate Analogs as Anticancer Agents to Metabolically Target HK-2 Activity in Glioblastoma Cells. Frontiers in Pharmacology. 13:828400. https://doi.org/10.3389/fphar.2022.828400.

[35]

Wagner, G., Fenzl, A., Lindroos-Christensen, J., Einwallner, E., Husa, J., Witzeneder, N., et al. 2021. LMO3 reprograms visceral adipocyte metabolism during obesity. Journal of Molecular Medicine (Berlin, Germany). https://doi.org/10.1007/s00109-021-02089-9.

[36]

Schelch, K., Vogel, L., Schneller, A., Brankovic, J., Mohr, T., Mayer, R.L., et al. 2021. EGF Induces Migration Independent of EMT or Invasion in A549 Lung Adenocarcinoma Cells. Frontiers in Cell and Developmental Biology. 9. https://doi.org/10.3389/fcell.2021.634371.

[37]

Baier, D., Müller, T., Mohr, T., Windberger, U. 2021. Red Blood Cell Stiffness and Adhesion Are Species-Specific Properties Strongly Affected by Temperature and Medium Changes in Single Cell Force Spectroscopy. Molecules. 26(9:2771. https://doi.org/10.3390/molecules26092771.

[38]

Mohr, T., Katz, S., Paulitschke, V., Aizarani, N., Tolios, A. 2021. Systematic Analysis of the Transcriptome Profiles and Co-Expression Networks of Tumour Endothelial Cells Identifies Several Tumour-Associated Modules and Potential Therapeutic Targets in Hepatocellular Carcinoma. Cancers. 13(8:1768. https://doi.org/10.3390/cancers13081768.

[39]

Ciardiello, D., Blauensteiner, B., Matrone, N., Belli, V., Mohr, T., Vitiello, P.P., et al. 2021. Dual inhibition of TGF\(\beta\) and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype. Medical Oncology (Northwood, London, England). 38(3. https://doi.org/10.1007/s12032-021-01464-3.

[40]

Vasconcelos, M.H., Alcaro, S., Arechavala-Gomeza, V., Baumbach, J., Borges, F., Brevini, T.A.L., et al. 2020. Joining European Scientific Forces to Face Pandemics. Trends in Microbiology. 0(0. https://doi.org/10.1016/j.tim.2020.10.008.

[41]

Paur, J., Valler, M., Sienel, R., Taxauer, K., Holzmann, K., Marian, B., et al. 2020. Interaction of FGF9 with FGFR3-IIIb/IIIc, a putative driver of growth and aggressive behavior of hepatocellular carcinoma. Liver International: Official Journal of the International Association for the Study of the Liver. https://doi.org/10.1111/liv.14505.

[42]

Pflügler, S., Svinka, J., Scharf, I., Crncec, I., Filipits, M., Charoentong, P., et al. 2020. IDO1+ Paneth cells promote immune escape of colorectal cancer. Communications Biology. 3. https://doi.org/10.1038/s42003-020-0989-y.

[43]

Oberhuber, M., Pecoraro, M., Rusz, M., Oberhuber, G., Wieselberg, M., Haslinger, P., et al. 2020. STAT3-dependent analysis reveals PDK4 as independent predictor of recurrence in prostate cancer. Molecular Systems Biology. 16(4:e9247. https://doi.org/10.15252/msb.20199247.

[44]

Pirker, C., Bilecz, A., Grusch, M., Mohr, T., Heidenreich, B., Laszlo, V., et al. 2020. Telomerase reverse transcriptase promoter mutations identify a genomically defined and highly aggressive human pleural mesothelioma subgroup. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research. https://doi.org/10.1158/1078-0432.CCR-19-3573.

[45]

Englinger, B., Laemmerer, A., Moser, P., Kallus, S., Röhrl, C., Pirker, C., et al. 2020. Lipid droplet-mediated scavenging as novel intrinsic and adaptive resistance factor against the multikinase inhibitor ponatinib. International Journal of Cancer. https://doi.org/10.1002/ijc.32924.

[46]

Tolios, A., De Las Rivas, J., Hovig, E., Trouillas, P., Scorilas, A., Mohr, T. 2020. Computational approaches in cancer multidrug resistance research: Identification of potential biomarkers, drug targets and drug-target interactions. Drug Resistance Updates. 48:100662. https://doi.org/10.1016/j.drup.2019.100662.

[47]

Klufa, J., Bauer, T., Hanson, B., Herbold, C., Starkl, P., Lichtenberger, B., et al. 2019. Hair eruption initiates and commensal skin microbiota aggravate adverse events of anti-EGFR therapy. Science Translational Medicine. 11(522. https://doi.org/10.1126/scitranslmed.aax2693.

[48]

Jomrich, G., Hudec, X., Harpain, F., Winkler, D., Timelthaler, G., Mohr, T., et al. 2019. Expression of FGF8, FGF18, and FGFR4 in Gastroesophageal Adenocarcinomas. Cells. 8(9:1092. https://doi.org/10.3390/cells8091092.

[49]

Oberhuber, M., Pecoraro, M., Rusz, M., Oberhuber, G., Wieselberg, M., Haslinger, P., et al. 2019. STAT3-dependent systems-level analysis reveals PDK4 as an independent predictor of biochemical recurrence in prostate cancer. bioRxiv. 770701. https://doi.org/10.1101/770701.

[50]

Paulitschke, V., Eichhoff, O., Gerner, C., Paulitschke, P., Bileck, A., Mohr, T., et al. 2019. Proteomic identification of a marker signature for MAPKi resistance in melanoma. The EMBO journal. e95874. https://doi.org/10.15252/embj.201695874.

[51]

Linder, M., Glitzner, E., Srivatsa, S., Bakiri, L., Matsuoka, K., Shahrouzi, P., et al. 2018. EGFR is required for FOS-dependent bone tumor development via RSK2/CREB signaling. EMBO molecular medicine. 10(11. https://doi.org/10.15252/emmm.201809408.

[52]

Hager, S., Korbula, K., Bielec, B., Grusch, M., Pirker, C., Schosserer, M., et al. 2018. The thiosemicarbazone Me2NNMe2 induces paraptosis by disrupting the ER thiol redox homeostasis based on protein disulfide isomerase inhibition. Cell Death & Disease. 9(11:1052. https://doi.org/10.1038/s41419-018-1102-z.

[53]

Heilos, D., Röhrl, C., Pirker, C., Englinger, B., Baier, D., Mohr, T., et al. 2018. Altered membrane rigidity via enhanced endogenous cholesterol synthesis drives cancer cell resistance to destruxins. Oncotarget. 9(39:25661–25680. https://doi.org/10.18632/oncotarget.25432.

[54]

Schelch, K., Wagner, C., Hager, S., Pirker, C., Siess, K., Lang, E., et al. 2018. FGF2 and EGF induce epithelial-mesenchymal transition in malignant pleural mesothelioma cells via a MAPKinase/MMP1 signal. Carcinogenesis. 39(4:534–545. https://doi.org/10.1093/carcin/bgy018.

[55]

Koch, M., Umek, W., Hanzal, E., Mohr, T., Seyfert, S., Koelbl, H., et al. 2018. Serum proteomic pattern in female stress urinary incontinence. Electrophoresis. https://doi.org/10.1002/elps.201700423.

[56]

Jacobi, N., Seeboeck, R., Hofmann, E., Schweiger, H., Smolinska, V., Mohr, T., et al. 2017. Organotypic three-dimensional cancer cell cultures mirror drug responses in vivo: Lessons learned from the inhibition of EGFR signaling. Oncotarget. 8(64:107423–107440. https://doi.org/10.18632/oncotarget.22475.

[57]

Ghassemi, S., Vejdovszky, K., Sahin, E., Ratzinger, L., Schelch, K., Mohr, T., et al. 2017. FGF5 is expressed in melanoma and enhances malignancy in vitro and in vivo. Oncotarget. 8(50:87750–87762. https://doi.org/10.18632/oncotarget.21184.

[58]

Schoenhacker-Alte, B., Mohr, T., Pirker, C., Kryeziu, K., Kuhn, P.-S., Buck, A., et al. 2017. Sensitivity towards the GRP78 inhibitor KP1339/IT-139 is characterized by apoptosis induction via caspase 8 upon disruption of ER homeostasis. Cancer Letters. https://doi.org/10.1016/j.canlet.2017.07.009.

[59]

Gojo, J., Lötsch, D., Spiegl-Kreinecker, S., Pajtler, K.W., Neumayer, K., Korbel, P., et al. 2017. Telomerase activation in posterior fossa group A ependymomas is associated with dismal prognosis and chromosome 1q gain. Neuro-Oncology. https://doi.org/10.1093/neuonc/nox027.

[60]

Englinger, B., Mair, M., Miklos, W., Pirker, C., Mohr, T., van Schoonhoven, S., et al. 2017. Loss of CUL4A expression is underlying cisplatin hypersensitivity in colorectal carcinoma cells with acquired trabectedin resistance. British Journal of Cancer. 116(4:489–500. https://doi.org/10.1038/bjc.2016.449.

[61]

Drev, D., Bileck, A., Erdem, Z.N., Mohr, T., Timelthaler, G., Beer, A., et al. 2017. Proteomic profiling identifies markers for inflammation-related tumor-fibroblast interaction. Clinical Proteomics. 14:33. https://doi.org/10.1186/s12014-017-9168-7.

[62]

Mohr, T., Haudek-Prinz, V., Slany, A., Grillari, J., Micksche, M., Gerner, C. 2017. Proteome profiling in IL-1\(\beta\) and VEGF-activated human umbilical vein endothelial cells delineates the interlink between inflammation and angiogenesis. PloS One. 12(6:e0179065. https://doi.org/10.1371/journal.pone.0179065.

[63]

Themanns, M., Mueller, K.M., Kessler, S.M., Golob-Schwarzl, N., Mohr, T., Kaltenecker, D., et al. 2016. Hepatic Deletion of Janus Kinase 2 Counteracts Oxidative Stress in Mice. Scientific Reports. 6:34719. https://doi.org/10.1038/srep34719.

[64]

Englinger, B., Lötsch, D., Pirker, C., Mohr, T., van Schoonhoven, S., Boidol, B., et al. 2016. Acquired nintedanib resistance in FGFR1-driven small cell lung cancer: Role of endothelin-A receptor-activated ABCB1 expression. Oncotarget. https://doi.org/10.18632/oncotarget.10324.

[65]

Koch, M., Mitulovic, G., Hanzal, E., Umek, W., Seyfert, S., Mohr, T., et al. 2016. Urinary proteomic pattern in female stress urinary incontinence: A pilot study. International Urogynecology Journal. https://doi.org/10.1007/s00192-016-3033-5.

[66]

Kryeziu, K., Pirker, C., Englinger, B., Schoonhoven, S. van, Spitzwieser, M., Mohr, T., et al. 2016. Chronic arsenic trioxide exposure leads to enhanced aggressiveness via Met oncogene addiction in cancer cells. Oncotarget. 5(0.

[67]

Mathieu, V., Chantôme, A., Lefranc, F., Cimmino, A., Miklos, W., Paulitschke, V., et al. 2015. Sphaeropsidin A shows promising activity against drug-resistant cancer cells by targeting regulatory volume increase. Cellular and molecular life sciences: CMLS. https://doi.org/10.1007/s00018-015-1902-6.

[68]

Pathria, P., Gotthardt, D., Prchal-Murphy, M., Putz, E.-M., Holcmann, M., Schlederer, M., et al. 2015. Myeloid STAT3 promotes formation of colitis-associated colorectal cancer in mice. OncoImmunology. 4(4:e998529. https://doi.org/10.1080/2162402X.2014.998529.

[69]

Grabner, B., Schramek, D., Mueller, K.M., Moll, H.P., Svinka, J., Hoffmann, T., et al. 2015. Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis. Nature Communications. 6. https://doi.org/10.1038/ncomms7285.

[70]

Dornetshuber-Fleiss, R., Heilos, D., Mohr, T., Richter, L., Süssmuth, R.D., Zlesak, M., et al. 2015. The naturally born fusariotoxin enniatin B and sorafenib exert synergistic activity against cervical cancer in vitro and in vivo. Biochemical Pharmacology. 93(3:318–331. https://doi.org/10.1016/j.bcp.2014.12.013.

[71]

Spiegl-Kreinecker, S., Lötsch, D., Ghanim, B., Pirker, C., Mohr, T., Laaber, M., et al. 2015. Prognostic quality of activating TERT promoter mutations in glioblastoma: Interaction with the Rs2853669 polymorphism and patient age at diagnosis. Neuro-Oncology. nov010. https://doi.org/10.1093/neuonc/nov010.

[72]

Schosserer, M., Minois, N., Angerer, T.B., Amring, M., Dellago, H., Harreither, E., et al. 2015. Methylation of ribosomal RNA by NSUN5 is a conserved mechanism modulating organismal lifespan. Nature Communications. 6:6158. https://doi.org/10.1038/ncomms7158.

[73]

Paulitschke, V., Gerner, C., Hofstätter, E., Mohr, T., Mayer, R., Pehamberger, H., et al. 2014. Proteome profiling of keratinocytes transforming to malignancy. ELECTROPHORESIS. n/a–n/a. https://doi.org/10.1002/elps.201400309.

[74]

Gauglhofer, C., Paur, J., Schrottmaier, W.C., Wingelhofer, B., Huber, D., Naegelen, I., et al. 2014. Fibroblast growth factor receptor 4: A putative key driver for the aggressive phenotype of hepatocellular carcinoma. Carcinogenesis. https://doi.org/10.1093/carcin/bgu151.

[75]

Heffeter, P., Atil, B., Kryeziu, K., Groza, D., Koellensperger, G., Körner, W., et al. 2013. The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo. European journal of cancer (Oxford, England: 1990). 49(15:3366–3375. https://doi.org/10.1016/j.ejca.2013.05.018.

[76]

Loetsch, D., Steiner, E., Holzmann, K., Spiegl-Kreinecker, S., Pirker, C., Hlavaty, J., et al. 2013. Major vault protein supports glioblastoma survival and migration by upregulating the EGFR/PI3K signalling axis. Oncotarget. 4(11:1904–1918.

[77]

Mohr, T., Desser, L. 2013. Plant proteolytic enzyme papain abrogates angiogenic activation of human umbilical vein endothelial cells (HUVEC) in vitro. BMC complementary and alternative medicine. 13(1:231. https://doi.org/10.1186/1472-6882-13-231.

[78]

Dornetshuber-Fleiss, R., Heffeter, P., Mohr, T., Hazemi, P., Kryeziu, K., Seger, C., et al. 2013. Destruxins: Fungal-derived cyclohexadepsipeptides with multifaceted anticancer and antiangiogenic activities. Biochemical pharmacology. 86(3:361–377. https://doi.org/10.1016/j.bcp.2013.05.022.

[79]

Paulitschke, V., Haudek-Prinz, V., Griss, J., Berger, W., Mohr, T., Pehamberger, H., et al. 2013. Functional classification of cellular proteome profiles support the identification of drug resistance signatures in melanoma cells. Journal of proteome research. 12(7:3264–3276. https://doi.org/10.1021/pr400124w.

[80]

Paulitschke, V., Haudek-Prinz, V., Griss, J., Berger, W., Mohr, T., Pehamberger, H., et al. 2013. Identification of a drug resistance signature by proteome analysis. Journal of Investigative Dermatology. 133:S236–S236.

[81]

Mathieu, V., de Lassalle, E.M., Toelen, J., Mohr, T., Bellahcène, A., Van Goietsenoven, G., et al. 2012. Galectin-1 in Melanoma Biology and Related Neo-Angiogenesis Processes. The Journal of investigative dermatology. https://doi.org/10.1038/jid.2012.142.

[82]

Slany, A., Haudek-Prinz, V., Griss, J., Mohr, T., Meshcheryakova, A., Zielinski, C., et al. 2011. Extracellular matrix remodeling and stromal cell-derived tumor promotion in the bone marrow reflect the progression of MGUS to multiple myeloma - a proteome profiling study. Onkologie. 34:18–18.

[83]

Pirker, A., Zaschka, M., Mikulits, N., Mohr, T., Gerner, C., Wimmer, H. 2011. CELL TYPE SPECIFICITY OF INFLAMMATORY SECRETOME PROFILES OF PRIMARY HUMAN ENDOTHELIAL AND DENDRITIC CELLS. Clinical Chemistry and Laboratory Medicine. 49:S781–S781.

[84]

Zaschka, M., Pirker, A., Mohr, T., Gerner, C., Wimmer, H. 2011. INFLAMMATORY ACTIVATION OF HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS IS ACCOMPANIED BY AN ALTERED GROWTH FACTORS SECRETION PROFILE. Clinical Chemistry and Laboratory Medicine. 49:S782–S782.

[85]

Gauglhofer, C., Sagmeister, S., Schrottmaier, W., Fischer, C., Rodgarkia-Dara, C., Mohr, T., et al. 2011. Up-regulation of the fibroblast growth factor 8 subfamily in human hepatocellular carcinoma for cell survival and neoangiogenesis. Hepatology (Baltimore, Md.). 53(3:854–864. https://doi.org/10.1002/hep.24099.

[86]

Drach, J., Slany, A., Mohr, T., Griss, J., Zielinski, C.C., Gerner, C. 2009. Secretome Analyses of Primary Bone Marrow Fibroblasts Isolated From MGUS and Multiple Myeloma Show a Stepwise Occurrence of Alterations. Blood. 114(22:716–716.

[87]

Drach, J., Slany, A., Mohr, T., Griss, J., Ackermann, J., Zielinski, C., et al. 2009. SECRETOME ANALYSES OF PRIMARY BONE MARROW FIBROBLASTS ISOLATED FROM MGUS AND MULTIPLE MYELOMA PATIENTS SUPPORT THE ROLE OF THE MICROENVIRONMENT FOR MYELOMA PATHOGENESIS. Haematologica-the Hematology Journal. 94:146–146.

[88]

Wimmer, H., Gundacker, N., Griss, J., Haudek, V., Stättner, S., Mohr, T., et al. 2009. Introducing the CPL/MUW proteome database: Interpretation of human liver and liver cancer proteome profiles by referring to isolated primary cells. Electrophoresis. 30(12:2076–2089.

[89]

Mohr, T., Stättner, S., Gundacker, N., Haudek, V., Slany, A., Brostjan, C., et al. 2009. How do Endothelial Cells Shape the Tissue Microenvironment? A Proteomic Approach. Cancer Microenvironment. 2 (Suppl. 1):S88–9.

[90]

Paulitschke, V., Kunstfeld, R., Mohr, T., Slany, A., Micksche, M., Drach, J., et al. 2009. Entering a new era of rational biomarker discovery for early detection of melanoma metastases: Secretome analysis of associated stroma cells. Journal of Proteome Research. 8(5:2501–10.

[91]

Slany, A., Haudek, V.J., Gundacker, N.C., Griss, J., Mohr, T., Wimmer, H., et al. 2009. Introducing a new parameter for quality control of proteome profiles: Consideration of commonly expressed proteins. Electrophoresis. 30(8:1306–28.

[92]

Allerstorfer, S., Sonvilla, G., Fischer, H., Spiegl-Kreinecker, S., Gauglhofer, C., Setinek, U., et al. 2008. FGF5 as an oncogenic factor in human glioblastoma multiforme: Autocrine and paracrine activities. Oncogene. 27(30:4180–90.

[93]

Gerner, C., Slany, A., Mohr, T., Schwarzmeier, L.D., Zielinski, C., Drach, J. 2008. Proteome profiling of multiple myeloma and the associated microenvironment in bone marrow. Cytokine. 43(3:323.

[94]

Sagmeister, S., Eisenbauer, M., Pirker, C., Mohr, T., Holzmann, K., Zwickl, H., et al. 2008. New cellular tools reveal complex epithelial-mesenchymal interactions in hepatocarcinogenesis. British Journal of Cancer. 99(1:151–9.

[95]

Haigl, B., Mayer, C.E., Mohr, T., Micksche, M., Attems, J., Berger, W., et al. 2007. Mechanisms involved in the regulation of Sprouty4 expression. FEBS JOURNAL. 274(Suppl. 1:353.

[96]

Mohr, T., Gundacker, N., Haudek, V., Bayer, E., Lenz, C., Horvath, R., et al. 2007. Molecular Profiling in Human Tumor Derived Vascular Endothelial Cells (HTEC). American Association for Cancer Research Annual Meeting: Proceedings; 2007 Apr 14-18; Los Angeles, CA. Philadelphia (PA).

[97]

Stättner, S., Mohr, T., Gundacker, N., Haudek, V., Bayer, E., Brostjan, C., et al. 2007. Proteomic Profiling of the Secretome of Human Liver Endothelial Cells (HLEC).

[98]

Mohr, T., Traxler, E., Bayer, E., Lenz, C., Horvath, R., Gerner, C., et al. 2004. Molecular Profiling in Quiescent and VEGF-activated Human Tumor Derived Vascular Endothelial Cells (HTDEC). Proceedings Of The Third International Conference On Tumor Microenvironment: Progression, Therapy And Prevention.

[99]

Traxler, E., Bayer, E., Stockl, J., Mohr, T., Lenz, C., Gerner, C. 2004. Towards a standardized human proteome database: Quantitative proteome profiling of living cells. Proteomics. 4(5:1314–1323.

[100]

Bradtke, J., Balz, H., Fonatsch, C., Heinze, B., Jauch, A., Mohr, B., et al. 2003. Computer aided analysis of additional chromosome aberrations in Philadelphia chromosome positive acute lymphoblastic leukaemia using a simplified computer readable cytogenetic notation. BMC Bioinformatics. 4:4. https://doi.org/10.1186/1471-2105-4-4.

[101]

Desser, L., Holomanova, D., Zavadova, E., Pavelka, K., Mohr, T., Herbacek, I. 2001. Oral therapy with proteolytic enzymes decreases excessive TGF-beta levels in human blood. Cancer Chemotherapy and Pharmacology. 47 Suppl:S10–15.

[102]

Desser, L., Herbacek, I., Mohr, T., Wrba, H. 1999. Proteolytic enzymes (Wobe-Mugos (R)) reduce immuno-suppression in cancer patients via a reduction of TGF-beta expression. Clinical Cancer Research. 5:3763S–3763S.

[103]

Berger, W., Setinek, U., Elbling, L., Mohr, T., Kindas-Mugge, I. 1999. Gain of an intracrine, proliferative loop involving FGF-2 and FGF-receptors in human non-small cell sung cancer (NSCLC) cells. European Journal of Cancer. 35:S108–S108. https://doi.org/10.1016/S0959-8049(99)80816-8.

[104]

Berger, W., Setinek, U., Mohr, T., Kindas-MÃ\frac{1}{4}gge, I., Vetterlein, M., Dekan, G., et al. 1999. Evidence for a role of FGF-2 and FGF receptors in the proliferation of non-small cell lung cancer cells. International Journal of Cancer. Journal International du Cancer. 83(3:415–23.

[105]

Desser, L., Herbacek, I., Zavadova, E., Mohr, T. 1999. Polyenzyme preparations interrupt the autocrine loop of TGF-beta production in melanoma cells by conversing alpha2Macroglobulin (a2M) into the fast-form which binds TGF-beta irreversible. European Journal of Cancer. 35(Suppl. 4:1526.

[106]

Mitteregger, R., White, A., Weber, C., Rossmanith, E., Mohr, T., Micksche, M., et al. 1999. In vitro cell culture systems as the basis for an extracorporeal blood purification strategy in multiorgan failure treatment. Therapeutic Apheresis : Official Journal of the International Society for Apheresis and the Japanese Society for Apheresis. 3(3:257–63.

[107]

Sakalova, A., Herbacek, I., Desser, L., Holomanova, D., Mohr, T. 1999. Progression markers in serum of patients with multiple myeloma. European Journal of Cancer. 35(Suppl. 4:418.

[108]

Sakalova, A., Desser, L., Zavadova, E., Holomanova, D., Mohr, T. 1998. Enzyme therapy improved remission time, soluble TNF-receptors and beta 2-microglobulin concentration in chemotherapy treated multiple myeloma patients. British Journal of Haematology. 102(1, Suppl. S:353.

[109]

Desser, L., Sakalova, A., Zavadova, E., Holomanova, T., Mohr, T. 1995. Combination therapy with cytostatic drugs and a polyenzyme preparation decreases concentration of soluble tumor necrosis factor receptors P55 and P75 in serum of patients with multiple myeloma. European Journal of Cancer. 31A(Suppl. 5:807.

[110]

Micksche, M., MinaiPour, M., KindasMugge, I., Mohr, T., Guglia, P., Vetterlein, M., et al. 1995. Production of basic fibroblast growth factor by human non small cell lung cancer cells. European Journal of Cancer. 31A(Suppl. 5:227.

[111]

Zavadova, E., Desser, L., Mohr, T. 1995. Stimulation of human neutrophils functions in vitro and after oral administration of a polyenzyme preparation. European Journal of Cancer. 31A(Suppl. 5:598.

[112]

Zavadova, E., Desser, L., Mohr, T. 1995. Stimulation of reactive oxygen species production and cytotoxicity in human neutrophils in vitro and after oral administration of a polyenzyme preparation. Cancer Biotherapy. 10(2:147–152.